JUNE 11-14, 2022 ATLANTA, GEORGIA
Continuing Medical Education
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.
The Endocrine Society designates this activity for a maximum of 110.0 AMA PRA Category 1 Credits*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 27.25 Maintenance of Certification (MOC) points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
*110 AMA PRA Category 1 credits are exclusive to premium registrants. Standard registrants are eligible for up to 27.25 AMA PRA Category 1 credits.
CREDIT CLAIM DEADLINES
- August 14, 2022: Standard registration credit claim expiration
- December 31, 2022: Premium registration credit claim expiration
CREDIT CLAIM INSTRUCTIONS1. Visit education.endocrine.org
2. Select "My Courses" or the Home icon on the left-hand side
3. Search for and click on ENDO 2022
4. Complete the evaluation
5. Claim credit commensurate with your participation
STATEMENT OF INDEPENDENCEAs a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.
DISCLOSURE POLICYThe faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 24 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
- The following AMSC members reported relevant financial relationships:
Antonio Bianco, MD, PhD, Consulting Fee: Allergan, BLA Technology, IBSA Foudnation, Synthonics
Kristien Boelaert, MD, PhD, Advisory Board: Pfizer, EISAI
Massimiliano Caprio, MD, PhD, Grant Recipient: Bayer AG
Bart Clarke, MD, Advisory Board: Bristol-Myers Squibb; Consulting Fee: Shire/Takeda, Inc., Calcilytix, Inc., Amolyt, Inc.
Carolyn L. Cummins, PhD, Member, American Association of Pharmaceutical Scientists, Canadian Society of Pharmaceutical Sciences; Reviewer and Grantee: Canadian Institutes of Health Research
Dawn Davis, MD, PhD, Employee: Department of Veterans Affairs; Grant Recipient: Department of Veterans Affairs, NIH
Scott M. Dehm, PhD, Executive Committee: Society for Basic Urologic Research; Grantee and Reviewer: NIH; Consultant: Janssen Research and Development LLC, Celgene
Marie B. Demay, MD, Reviewer and Grantee, NIH
Daniel Dumesic, MD, Advisory Board: Spruce BioSciences Inc.; Grant Recipient: NIH
Lauren Fishbein, MD, PhD, Advisory Board: PheoPara Alliance; Consulting Fee: Lantheus/Azedra; Member: American Association of Clinical Endocrinologists, North American Neuroendocrine Tumor Society, Women in Endocrinology; Co-Lead PheoPara Working Group: A5
Aime T. Franco, PhD, Board of Directors, Co-Chair Trainees and Education Committee, Co-Chair of ATA Grant Program Review Task Force: American Thyroid Association
Matthew Freeby, MD, Grant Recipient: Novo Nordisk, Abbott Diabetes
Daniel E. Frigo, PhD, Consultant and Grant Recipient: GTx, Inc.
Adda Grimberg, MD, Advisory Board: Pfizer; Consulting Fee: Sandoz; Grant Recipient: Eunice Kennedy Shriver National Institute of Child Health and Human Development
Aylin C. Hanyaloglu, PhD, Grant Panel Member: Studium Institute for Advanced Studies; Associate Editor: Frontiers for Endocrinology; Consultant: Merck
Niki Karavitaki, FRCP, PhD, Advisory Board: Recordati Rare Diseases, Pfizer, Ipsen; Speaker: HRA Pharma, Pfizer, Ipsen
Marta Korbonits, MD, PhD, Speaker: Pfizer, Ipsen; Associate Editor: JES, Endocrine Society; Scientific Advisor: ONO, NorvoNordisk, Corcept; Investigator: Crinetics
Stephane A. Laporte, PhD, Editorial Board Member: Journal of Biological Chemistry; Collaborator: Domain Therapeutics NA Inc.
Monica M. Laronda, PhD, Advisory Board Member: Dimension Inx; Section Editor: Reproductive Biomedicine Online (RBMO)
Maria Veronica Mericq, MD, Advisory Board: Pfizer, Sandoz, Merck, Novo Nordisk; Consultant Fee: Novartis/Sandoz; Grant Recipient: Merck
Nicola Napoli, MD, PhD, Advisory Board: UCB; Consultant: Abiogen, UCB
Gabrielle Page-Wilson, MD, Advisory Board: Strongbridge Biopharma, Recordati Rare Diseases, Inc., Xeris BioPharma; Consultant: Xeris BioPharma
Robin Peeters, MD, PhD, Advisory Board: Sanofi Genzyme, Bayer; Speaker: Berlin-Chemie, Goodlife Fertility BV, Institut Biochimique SA (IBSA), Sanofi Genzyme, Bayer, EISAI, Program Organizing Committee Annual Meeting: American Thyroid Association; Focus Area Lead: Program Organizing Committee, European Society for Endocrinology; Member: European Thyroid Association
Jennifer Sherr, MD, PhD, Advisory Board: Bigfoot Biomedical, Lilly, Insulet, Cecelia Health; Consultant Fee: Medtronic Diabetes, Sanofi; Grant Recipient: JDRF, Reviewer: JDRF
Robert Wermers, MD, Meeting Program Committee: American Association of Clinical Endocrinology Bone and Calcium Disease State Network; Editor: Bone and Calcium ASAP Section
Selma F. Witchel, MD, Annual Meeting Program Committee: Pediatric Endocrine Society; Member: Androgen Excess-PCOS Society; Editorial Board Member, Journal of Clinical Endocrinology & Metabolism, Journal of the Endocrine Society, Sex Development; Associate Editor: Steroids
Maria-Christina Zennaro, MD, PhD, Member: Societé Française d'Endocrinology, Societé Française de Caridologie, European Network for the Study of Adrenal Tumors; Executive Committee: International Aldosterone Conference; President: European Section of Aldosterone Council (ESAC)-France; French network on adrenal tumors COMETE
Bulent Okan Yildiz, MD, Reproductive and Developmental Endocrinology Clinical Lead: European Society of Endocrinology
- The following AMSC members reported no relevant financial relationships:
- Disclosure information for presenters is included in their individual recorded presentations.
- Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.
USE OF PROFESSIONAL JUDGMENT:The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.
DRUGS AND DOSAGES:When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.
POLICY ON UNLABELED/OFF-LABEL USEThe Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.
PRIVACY AND CONFIDENTIALITY STATEMENTThe Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.
Event InformationJune 11-14, 2022
Georgia World Congress Center
Important DatesJune 19, 2022
- Standard non-member registrant access to the virtual platform concludes
June 30, 2022
- Standard member registrant access to the virtual platform concludes
August 14, 2022
- Standard registration credit claim expiration deadline
December 31, 2022
- Premium member and non-member access to the virtual platform concludes
- Premium registration credit claim expiration deadline